LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Lista de Ações・Abeona Therapeutics Inc

Abeona Therapeutics Inc

Fechado

6.06 4.3

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.6

Máximo

6.1

Indicadores-chave
By Trading Economics
Funcionários	136

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+257.51% upside

Dividendos
By Dow Jones
Próximos Ganhos	11 de ago. de 2025

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	26M 240M
Abertura anterior	1.76
Fecho anterior	6.06

Abeona Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2025, 22:52 UTC

Ganhos

Grandes Movimentos do Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 de mai. de 2025, 20:37 UTC

Principais Notícias

Ganhos

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 de mai. de 2025, 00:00 UTC

Conversa de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 de mai. de 2025, 23:47 UTC

Conversa de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2025, 23:38 UTC

Conversa de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 de mai. de 2025, 23:14 UTC

Principais Notícias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 de mai. de 2025, 22:46 UTC

Principais Notícias

Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 de mai. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 de mai. de 2025, 21:58 UTC

Ganhos

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 de mai. de 2025, 21:24 UTC

Ganhos

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 de mai. de 2025, 20:56 UTC

Conversa de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 de mai. de 2025, 20:54 UTC

Conversa de Mercado

Ganhos

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 de mai. de 2025, 20:54 UTC

Ganhos

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 de mai. de 2025, 20:51 UTC

Ganhos

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 de mai. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

15 de mai. de 2025, 20:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 de mai. de 2025, 20:50 UTC

Ganhos

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 de mai. de 2025, 20:47 UTC

Ganhos

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 de mai. de 2025, 20:37 UTC

Ganhos

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 de mai. de 2025, 20:26 UTC

Principais Notícias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 de mai. de 2025, 20:25 UTC

Ganhos

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparação entre Pares

Variação de preço

Abeona Therapeutics Inc Previsão

Preço-alvo

By TipRanks

257.51% parte superior

Previsão para 12 meses

Média 20.7 USD 257.51%

Máximo 27.5 USD

Mínimo 16 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Abeona Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Abeona Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Sobre Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.